Navigation Links
Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
Date:3/24/2009

sional team of clinical trial monitors as part of the project to keep close surveillance on the patients. The manager of Sinobiopharma's Clinical Research Department, Mr. Lei Wang, reported on the Phase IV project clinical monitoring outcomes.

The experts' consensus was that the Phase IV study established Kutai as safe and effective for room temperature storage. The year-long clinical research project showed no significant differences between Kutai and imported Cisatracurium besylate, and no significant differences for Kutai safety and effectiveness when stored at either room temperature or a lower temperature.

All the participating parties followed the study design and promote inter-communication to ensure compliance with Good Clinical Practice (GCP).

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which
'/>"/>

SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
2. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
3. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
4. Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
5. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
6. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
7. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
8. Walter Reed Army Medical Center offers HIFU for Qualifying Men with Locally Recurrent Prostate Cancer in a Phase III Clinical Trial
9. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
10. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
11. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  Today the U.S. Food and Drug ... the prevention of serogroup B meningococcal disease ... vaccine Trumenba®, which received FDA approval in October, represent ... disease. "I have heard over and ...
(Date:1/23/2015)... 23, 2015 Research and Markets ( http://www.researchandmarkets.com/research/5dh22x/urinary_catheters ... Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and ... Size, Share, Growth, Trends and Forecast 2014 - 2020" ... At present, the global market for urinary catheters is ...
(Date:1/23/2015)... BETHESDA, Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for operable and inoperable solid ... will present at the 7 th Annual Phacilitate Immunotherapy ... NW Bio,s presentation at Phacilitate will take place on January ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... 2011 ChromaDex® Corp. (OTCBB: CDXC) today announced ... ChromaDex® the exclusive rights to a joint patent ... the method of inducing UDP-glucuronosyltransferase (UGT) activity using ... found in blueberries and demonstrated to have multiple ...
... Sept. 8, 2011 Abaxis, Inc. (NasdaqGS: ABAX), a ... today that Clint Serverson, chief executive officer,  will present ... Tuesday, September 13, 2011 at 10:20 a.m. ET at ... AbaxisAbaxis develops, manufactures, markets and sells portable blood analysis ...
Cached Medicine Technology:ChromaDex®'s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers 2ChromaDex®'s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers 3Abaxis to Present at 2011 Morgan Stanley Global Healthcare Unplugged Conference 2
(Date:1/22/2015)... PA (PRWEB) January 22, 2015 Woodloch Pines, ... Mountains, has been selected by TripAdvisor as the number one ... the 6th best in the world for their annual Travelers’ ... online travel community . The website is home to millions ...
(Date:1/22/2015)... January 22, 2015 The Incredible Bulk is ... Pakulski to increase lean muscle by up to 30lbs in ... the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. ... is a step-by-step, scientific diet formula that allows the body ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... Wins Competitive Bid to Support NIH Information Sharing ... one of the Washington region,s leading providers of ... blanket purchase agreement (BPA) by the National Institutes ... services. The BPA, effective February 18, 2009, covers ...
... Bio-Optronics, Inc., a leader in ... Site Clinical Trial Management System (CTMS) continues to ... in the areas of patient recruitment, advertising ROI, ... an area of concern for clinical trials. Clinical ...
... of bid price requirement gives Company until November 2009 ... VSCP ) today announced that The Nasdaq Stock ... extended the temporary suspension of the $1.00 minimum bid ... of the rule suspension by Nasdaq, VirtualScopics now has ...
... spiders, a tiny chirping frog and an elegant striped ... discovered during a Conservation International (CI) Rapid Assessment Program ... The discoveries were announced today following analysis of the ... 2008 during a month-long exploration of Papua New Guinea,s ...
... benefits from cutting-edge treatment MACON, Ga., March 25 ... twin sons Dawson and Dakota into the world in February ... that over time Dawson,s head was becoming increasingly flat on ... resting for prolonged periods in one position in an infant ...
... ABBOTT PARK, Ill., March 25 Abbott ( NYSE: ... Wednesday, April 15, 2009, before the market opens.The announcement will ... call at 8 a.m. Central time (9 a.m. Eastern), and ... www.abbottinvestor.com . An archived edition of the call ...
Cached Medicine News:Health News:NIH Awards Blanket Purchase Agreement (BPA) to Citizant 2Health News:Clinical Conductor Site Clinical Trial Management System (CTMS) Improves Clinical Trial Productivity at Research Sites 2Health News:VirtualScopics Receives Further Extension to Regain Compliance With Nasdaq 2Health News:Spiders, frogs and gecko among exciting discoveries found in Papua New Guinea 2Health News:Spiders, frogs and gecko among exciting discoveries found in Papua New Guinea 3Health News:STARscanner, STARband Cranial Helmets Making a Difference in the Lives of Children 2Health News:STARscanner, STARband Cranial Helmets Making a Difference in the Lives of Children 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: